Ascendis Pharma A/S : INCORPORATION BY REFERENCE - Form 6-K

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-228576,333-203040,333-210810,333-211512,333-213412,333-214843,333-216883,333-254101 and 333-261550) and Form F-3 (Registration Numbers 333-209336,333-211511,333-216882,333-223134,333-225284 and 333-256571) of Ascendis Pharma A/S (the "Company") (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

On November 14, 2022, the Company announced it has submitted a Marketing Authorisation Application with the European Medicines Agency for TransCon PTH (palopegteriparatide), an investigational prodrug designed to restore parathyroid hormone (PTH [1-34]) to physiological levels over 24 hours in adult patients with hypoparathyroidism.